<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529230</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-451</org_study_id>
    <nct_id>NCT00529230</nct_id>
  </id_info>
  <brief_title>Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes</brief_title>
  <official_title>Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      1. To determine the prevalence of secondary hypogonadism in male patients on chronic opioid&#xD;
      therapy for cancer-related pain syndromes.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      1. To determine the degree of sexual dysfunction, fatigue, and depression prevalent in male&#xD;
      patients on chronic opioid therapy for cancer-related pain syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown that non-cancer patients taking opioid pain medication for a long period&#xD;
      of time can have decreased libido and decreased sexual function.&#xD;
&#xD;
      Individuals may be asked to take part in this study even if they have not taken opioid pain&#xD;
      medications in the last twelve months. These individuals would also be enrolled to learn if&#xD;
      long-term treatment of cancer-related pain with opioid medications results in decreased sex&#xD;
      hormones, decreased sex drive, and increased fatigue or depression.&#xD;
&#xD;
      Participants in this study will be asked to complete a set of questions about their sexual&#xD;
      functions, physical symptoms, and psychological symptoms such as fatigue and depression. It&#xD;
      will take about 25 minutes to complete the questionnaires.&#xD;
&#xD;
      Participants will have blood drawn (about 2 teaspoons of blood) to test their sex hormone&#xD;
      level. Participants who are identified as having low sex hormone level (hypogonadism) will be&#xD;
      referred to an endocrinologist for standard hormone replacement therapy.&#xD;
&#xD;
      This is a one-time evaluation, no follow-up visit or questionnaires are required.&#xD;
&#xD;
      This is an investigational study. A total of 108 individuals will take part in this study.&#xD;
      All will be enrolled at UTMDACC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual rate.&#xD;
  </why_stopped>
  <start_date type="Actual">December 11, 2001</start_date>
  <completion_date type="Actual">February 19, 2004</completion_date>
  <primary_completion_date type="Actual">February 19, 2004</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of secondary hypogonadism in male patients on chronic opioid therapy for cancer-related pain syndromes</measure>
    <time_frame>3 Years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">46</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Hypogonadism</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Chronic opioid therapy + Gonadal function</arm_group_label>
    <description>Males on chronic opioid therapy for cancer-related pain syndromes</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>A set of questionnaires regarding sexual function, physical and psychological symptoms.</description>
    <arm_group_label>Chronic opioid therapy + Gonadal function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draws to assess gonadal function</intervention_name>
    <description>Testosterone, FSH, and LH levels at study onset.</description>
    <arm_group_label>Chronic opioid therapy + Gonadal function</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood draws to assess gonadal function.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Males on chronic opioid therapy for cancer-related pain syndromes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chronic pain greater than one year.&#xD;
&#xD;
          2. Male.&#xD;
&#xD;
          3. Cancer status must be stable or in remission. For this study, &quot;stable disease&quot; is&#xD;
             defined as identifiable disease at local or metastatic sites that has shown no&#xD;
             progression over the previous 3 months and there has been no cancer treatment for ³ 3&#xD;
             months.&#xD;
&#xD;
          4. Patients must be on chronic opioid therapy on a continuous basis in the preceding&#xD;
             twelve months with a Morphine Equivalent Daily Dose (MEDD) ³ 200.&#xD;
&#xD;
          5. Age &gt;/= 18. The questionnaires used in this study have been validated only in the&#xD;
             adult population. In addition, some of the questionnaires contain questions of a&#xD;
             sensitive nature and are not appropriate in the pediatric population.&#xD;
&#xD;
          6. Patients must be able to understand and sign the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who refuses to participate in the study or determined incapable of completing&#xD;
             the research.&#xD;
&#xD;
          2. Patients with pre-existing hypopituitarism. Causes include certain tumors (pituitary&#xD;
             adenomas, hypothalamic tumors), inflammatory diseases (granulomatous diseases),&#xD;
             vascular diseases (postpartum necrosis, carotid aneurysm), traumatic/destructive&#xD;
             events (prior surgery, trauma, or radiation), developmental anomalies, infiltration.&#xD;
&#xD;
          3. Patients who tare taking any drugs that may affect the hypothalamic-pituitary-gonadal&#xD;
             axis.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun Rajagopal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>October 24, 2018</last_update_submitted>
  <last_update_submitted_qc>October 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancer</keyword>
  <keyword>Chronic Opioid Therapy</keyword>
  <keyword>Secondary Hypogonadism</keyword>
  <keyword>Cancer-Related Pain Syndromes</keyword>
  <keyword>Questionnaire</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

